
Johnson & Johnson
JNJHealthcare|Drug Manufacturers - General|US
$276.22
+3.90 (+1.43%)
DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04
Next Earnings Report
Jan 26, 2027
EPS est. $2.91 · Revenue est. $26.42B
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Feb 11, 2026 (S-3ASR). Possible dilution.
Upcoming Data Readouts (17)
Nov 2026
Est. completion
NABreast Cancer (Locally Advanced or Metastatic)
Remote Monitoring and Symptom Management Digital Application
NCT07553572n=60
Dec 2026
Est. completion
Dysphotopsia
Clinical Evaluation of Low Contrast Visual Performance and Low Light Phenomena in Patients With Various Intraocular Lens Implants
NCT07213167n=120
Dec 2026
Est. completion
NALiver Disease Chronic
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
NCT05998330n=220
Dec 2026
Est. completion
Dec 2026
Est. completion
Feb 2027
Est. completion
P4Multiple Myeloma
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517n=75
Aug 2027
Est. completion
NAJuxtarenal Abdominal Aortic Aneurysm
University of Utah PS-IDE: Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms
NCT07065760n=15
Aug 2027
Est. completion
Feb 2028
Est. completion
Intracranial Aneurysm
A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms
NCT07228312n=200
Jul 2028
Est. completion
Atrial Fibrillation
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
NCT07511166n=300
Oct 2028
Est. completion
Cardiogenic Shock Post Myocardial Infarction
Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
NCT07655479n=115
Dec 2028
Est. completion
NAHeart Failure
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504n=250
Aug 2029
Est. completion
P2Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
NCT06993675n=50
Aug 2029
Est. completion
Apr 2030
Est. completion
NAAnkle Arthritis
Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study
NCT00552136n=250
Oct 2030
Est. completion
P1P2Plasma Cell Disorder
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
NCT07075510n=30
Jun 2031
Est. completion
NAOsteoarthritis, Hip
Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis Stem
NCT07828080n=210
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2025
NA
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
NCT06153797Dec 2024
NA
Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia
NCT02596802Recent Press Releases
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Nov 8, 2026 · PRNewsWire
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
Nov 7, 2026 · PRNewsWire
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Nov 7, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Nov 5, 2026 · PRNewsWire
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
Nov 5, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Nov 3, 2026 · GlobeNewsWire
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Nov 1, 2026 · Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Oct 29, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Oct 27, 2026 · GlobeNewsWire
Johnson & Johnson to Host Enterprise Business Review
Oct 27, 2026 · Business Wire
SEC Filings (73)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Oct 26, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Oct 21, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 13, 2026 | 8-K | Material event | DocumentIndex |
| Aug 11, 2026 | N-PX | DocumentIndex | |
| Aug 6, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Jul 29, 2026 | 8-K | Material event | DocumentIndex |
| Jul 28, 2026 | 8-K | Material event | DocumentIndex |
| Jul 23, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 15, 2026 | 8-K | Material event | DocumentIndex |
| Jun 25, 2026 | 11-K | DocumentIndex | |
| Jun 25, 2026 | 11-K | DocumentIndex | |
| May 27, 2026 | SD | DocumentIndex | |
| May 13, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| May 1, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 28, 2026 | 8-K | Material event | DocumentIndex |
| Apr 22, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 14, 2026 | 8-K | Material event | DocumentIndex |
| Apr 13, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 18, 2026 | 13F-HR/A | Institutional holdings report | DocumentIndex |
| Mar 18, 2026 | 13F-HR/A | Institutional holdings report | DocumentIndex |
| Mar 11, 2026 | ARS | Annual report to holders | DocumentIndex |
| Mar 11, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Mar 11, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Feb 13, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Feb 11, 2026 | S-3ASR | Shelf registration | DocumentIndex |
| Feb 11, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 21, 2026 | 8-K | Material event | DocumentIndex |
| Jan 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 13, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Oct 22, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 22, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 14, 2025 | 8-K | Material event | DocumentIndex |
| Sep 9, 2025 | 8-K | Material event | DocumentIndex |
| Aug 26, 2025 | N-PX | DocumentIndex | |
| Jul 24, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Jul 22, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Jul 16, 2025 | 8-K | Material event | DocumentIndex |